Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.33 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284261 | 1.00 | TSHR (0.41) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL13052067 | 0.86 | CA12 (0.39) | CA12CA1CA2CA9ENPP2 | |
| SCHEMBL27999363 | 0.78 | HPGD (0.38) | TSHR | |
| SCHEMBL26277105 | 0.77 | ACHE (0.41) | TSHRCA12CA1CA2CA9 | |
| SCHEMBL15752144 | 0.76 | ENPP2 (0.32) | ENPP2LPAR1LPAR2 | |
| SCHEMBL3686778 | 0.74 | — | — | |
| SCHEMBL21577394 | 0.74 | SMN1; SMN2 (0.41) | TSHRACHE | |
| SCHEMBL14748951 | 0.74 | FABP3 (0.36) | TSHRENPP2LPAR1LPAR2 | |
| SCHEMBL13055391 | 0.73 | TSHR (0.35) | TSHRACHE | |
| SCHEMBL3759105 | 0.72 | TSHR (0.41) | TSHRCA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8999323-B2 | Composition that can be cured by polymerisation for the production of biodegradable, biocompatible, cross-linkable polymers on the basis of polyvinyl alcohol | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2015-04-07 | — | — | US | disclosed |
| US-8999323-B2 | Composition that can be cured by polymerisation for the production of biodegradable, biocompatible, cross-linkable polymers on the basis of polyvinyl alcohol | TECHNISCHE UNIVERSITÄT WIEN (AT) | 2015-04-07 | — | — | US | disclosed |
| EP-2428235-B1 | Use of compounds hardened by means of polymerisation for producing biodegradable, biocompatible, networked polymers | UNIV WIEN TECH (AT) | 2014-06-04 | — | — | EP | disclosed |
| EP-2428235-A2 | Use of compounds hardened by means of polymerisation for producing biodegradable, biocompatible, networked polymers | Technische Universität Wien (AT) | 2012-03-14 | — | — | EP | disclosed |
| US-20100303804-A1 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITAT WIEN (AT) | 2010-12-02 | — | — | US | disclosed |
| US-20100303804-A1 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | TECHNISCHE UNIVERSITAT WIEN (AT) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303804-A1 | COMPOSITION THAT CAN BE CURED BY POLYMERISATION FOR THE PRODUCTION OF BIODEGRADABLE, BIOCOMPATIBLE, CROSS-LINKABLE POLYMERS ON THE BASIS OF POLYVINYL ALCOHOL | SCO2, CBR1, CBR3 | TSHR 4555/4885CA12 1262/4885CA1 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.